BOUL: Sales fell 25% YoY, but margins improved and OEM growth offset hematology weakness

About this update from Boule Diagnostics Ab

Q1 2025 saw a 25% organic sales decline, but operating margin improved to 15.1% due to restructuring and a favorable mix. OEM sales grew, while hematology sales dropped on delayed payments and a business model shift. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Boule Diagnostics Ab